Redburn Partners analyst Will Jones upgrades CRH (NYSE:CRH) from Neutral to Buy.
Johnson & Johnson’s Talc Cancer Claims Saga: $8.9B Settlement Under Scrutiny
Johnson & Johnson's (NYSE: JNJ) proposed $8.9 billion settlement of lawsuits alleging cancer-causing talc products faces a key test in a U.S.